MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Operating Income 2011-2026 | VIVO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.4 M | 93 M | 61.3 M | 32.7 M | 31.6 M | 37.4 M | 51.4 M | 56.1 M | 52.4 M | 57.3 M | 49.3 M | 40 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 93 M | 31.6 M | 51.4 M |
Quarterly Operating Income Meridian Bioscience
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -28.1 M | - | - | 36.1 M | 20.3 M | - | 15.7 M | 34.2 M | 34.7 M | 51.8 M | 34.7 M | 34.7 M | 5.39 M | 26.8 M | 6.46 M | 5.39 M | 10.6 M | 24.5 M | 8.74 M | 10.6 M | 8.06 M | 28.6 M | 4.3 M | 8.06 M | 10.1 M | 42.5 M | 13.7 M | 10.1 M | 13.6 M | 42.8 M | 14.4 M | 13.6 M | 12.7 M | 40.4 M | 13.1 M | 12.7 M | 11.6 M | 44 M | 15.7 M | 11.6 M | 13.1 M | 37.2 M | 12.6 M | 13.1 M | 9.8 M | 30.2 M | 10.1 M | 9.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 51.8 M | -28.1 M | 18.7 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
54 M | $ 9.26 | 1.09 % | $ 617 M |  USA |
|
Biodesix
BDSX
|
-34.5 M | $ 14.6 | -3.63 % | $ 1.89 B | USA |
 |
DarioHealth Corp.
DRIO
|
-36.7 M | $ 8.45 | 9.74 % | $ 33.7 M |  Israel |
 |
DexCom
DXCM
|
912 M | $ 66.09 | -1.12 % | $ 25.8 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 103.08 | 3.09 % | $ 8.5 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.36 B | $ 573.29 | -0.42 % | $ 46.1 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 124.4 | -1.43 % | $ 19.8 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 466.6 | -0.04 % | $ 13.5 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.62 | -1.28 % | $ 428 M | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.52 | 1.98 % | $ 392 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Natera
NTRA
|
-541 M | $ 196.15 | -0.62 % | $ 19.3 B | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 165.13 | -0.46 % | $ 8.18 B | USA |
 |
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.17 | -1.68 % | $ 812 M | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 1.35 | -2.88 % | $ 405 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 4.59 | 22.4 % | $ 2.46 M | USA |
 |
PerkinElmer
PKI
|
357 M | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 7.32 | -4.94 % | $ 434 M | USA |
 |
Interpace Biosciences
IDXG
|
8.11 M | $ 1.73 | 2.37 % | $ 7.59 M | USA |
 |
RadNet
RDNT
|
62 M | $ 59.41 | -2.06 % | $ 4.47 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
Celcuity
CELC
|
-172 M | $ 114.81 | 4.16 % | $ 4.53 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 6.56 | -2.96 % | $ 274 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 268.38 | 0.89 % | $ 22.3 B | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 7.76 | -0.13 % | $ 994 M | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 31.83 | -0.03 % | $ 1.62 B | USA |
 |
Psychemedics Corporation
PMD
|
-2.92 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
-7.62 M | $ 27.2 | -0.15 % | $ 35.3 M | USA |